Sweetech SAS

Sweetech SAS, based in France, develops innovative fermentation technology to produce oligosaccharides, which are essential in various health applications. The company focuses on eco-friendly solutions and aims to meet market demand for structurally pure sugars. Founded in 2021, Sweetech SAS is headquartered in Toulouse, France, and specializes in the production of oligosaccharides through fermentation technology. The company has secured EUR 2.

25 million in SEED funding, with Bpifrance and Iron Hands Capital as investors. Sweetech has participated in one funding deal, with its most recent round completed on January 19, 2026, raising a total of EUR 2. 25 million. Sweetech specializes in the production of oligosaccharides through its patented fermentation technology, aimed at being eco-friendly and cost-effective.

Their offerings address a notable gap in the market for rarely synthesized sugars, crucial for applications in the nutraceutical, cosmetic, and pharmaceutical sectors. By enabling large-scale industrial production of tailored oligosaccharides, Sweetech serves a diverse clientele in health-focused industries and researchers across various geographical regions. Sweetech generates revenue through direct partnerships and collaborations with health industry players, focusing on B2B transactions. Clients can order oligosaccharides in bulk or custom formulations, with contracts for ongoing supply agreements.

While specific pricing is not disclosed, the company emphasizes competitively priced products that leverage biotechnological innovations to maintain operational efficiency and support various sectors, ensuring a robust market presence. Following its recent SEED funding round of EUR 2. 25 million, Sweetech plans to enhance customer acquisition efforts and strengthen its research and development initiatives. The funding will aid in scaling its sustainable rare-sugar platform, with a focus on expanding into new markets and geographic regions.

The company is actively looking to penetrate additional segments within the nutraceutical and pharmaceutical industries by 2026, aligning its growth strategy with the evolving market demands.